Skip to content
lifestyle.gooddecisions.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kymera Therapeutics, Inc.
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
May 6, 2026
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
May 5, 2026
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
April 30, 2026
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
April 23, 2026
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
April 13, 2026
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 19, 2026
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
February 4, 2026
←
Previous Page
1
2